Vernalis plc is raising £30 million (US$47 million) in a stock sale to buy back its royalty stream for migraine drug frovatriptan and shore up its bank balance ahead of much-awaited data from its Phase IIb trial of V3381 in neuropathic pain. (BioWorld Today)